Biotech Co.* (Symbol)

Pharma Co. (Country)

Type/Product Area

Disclosed Funding (M)

Terms/Details (Date)

Alkermes Inc. (ALKS)

Eli Lilly & Co.

Collaboration to develop an inhaled formulation of insulin using Alkermes' AIR pulmonary drug delivery system

ND

Alkermes will receive funding for development, milestone payments and royalties; Lilly will receive exclusive worldwide rights to resulting products (4/2)

Amrad Corp. Ltd. (Australia; ASX:AMC)

GlaxoSmithKline plc (UK)

Collaboration and license agreement focused on two components of Amrad's suppressors of cytokine signaling platform technology

A$50 (US$25.44)

Amrad will receive research and development funding for two years and up to US$25.44M in milestone payments and royalties (3/12)

Arena Pharmaceuticals Inc. (ARNA)

Taisho Pharmaceutical Co. Ltd. (Japan)

Receptor-discovery research collaboration to identify a G protein-coupled receptor

ND

Following identification, cloning and sequencing, the collaboration will focus on applying Arena's CART technology to the receptor; Taisho will make an up-front payment (3/26)

BioMarin Pharmaceutical Inc. (BMRN)

W.R. Grace & Co.

Exercised option agreement for vibriolysin, an enzyme that has shown efficacy related to debridement and wound healing

ND

License includes U.S. and European patents, as well as pending patents in Canada and Japan (1/11)

Chiron Corp. (CHIR)

Japan Tobacco Inc. (Japan)

Nonexclusive license agreement for the research, development and commercialization of small-molecule therapeutics against a specified hepatitis C virus drug target contained in the HCV genome

ND

Japan Tobacco gains the license to operate under certain Chiron patents (3/7)

Cogent Neuroscience Inc.*

Elan Corp. plc (Ireland)

Agreement to form a joint venture to discover and develop therapeutic gene targets for a group of intractable brain disorders called polyglutamine repeat disorders

ND

Elan will provide research support and will make an undisclosed equity investment in Cogent (3/8)

Crucell NV (the Netherlands; CRXL)

Merck & Co. Inc.

Agreement to apply Crucell's PER.C6 technology to Merck's HIV-1 vaccine program

ND

Agreement includes an up-front fee, ongoing fees and royalty and milestone payments for Crucell; Merck has an option to extend the exclusivity to cover three unnamed disease areas (4/3)

Cyclacel Ltd. (UK)*

AstraZeneca plc (UK)

Research-stage cancer program in small-molecule inhibitors of the cell cycle

#8 (US$11.49)

Under terms of the two-year agreement, Cyclacel will receive up-front fees and milestones, as well as royalties (4/25**)

Cytomedix Inc. (OTC BB:CYDX)

DuPuy AcroMed Inc.

Licensing agreement to gain access to a family of DuPuy patents

ND

Cytomedix will license DuPuy patents in the fields of spinal and orthopedic surgeries and neurosurgery (3/22)

deCODE genetics Inc. (DCGN)

Roche Holding AG

Agreement to develop DNA-based diagnostic systems and products

$50

Five-year collaboration could be worth more than $50M in research and development funding and milestone payments (3/6)

Epimmune Inc. (EPMN)

Elan Corp. plc (Ireland)

License and option agreement for Epimmune's PADRE technology

ND

Agreement allows further evaluation of the technology for use in immunological treatments for Alzheimer's disease (4/5)

GeneData AG (Switzerland)*

Novartis Pharma AG (Switzerland)

Multiyear collaboration to functionally characterize the genomes of pathogenic bacteria, identify anti-bacterial targets and aid in selection of compounds to develop new antimicrobial drugs

ND

GeneData will supply its GeneData Phylosopher to analyze the genomes of pharmaceutically relevant pathogens (3/27)

Gene Logic Inc. (GLGC)

Sankyo Co. Ltd. (Japan)

Subscription agreement to the BioExpress Module and the TotExpress Module of Gene Logic's GeneExpress Suite of databases

ND

The databases will be used in Sankyo's drug discovery and development programs (4/2)

Immucell Corp. (ICCC)

Novatreat Ltd. (Finland)

License and supply agreement covering certain nutritional and risk reduction rights for functional food applications of ImmuCell's DiffGAM technology outside North America

$0.1

ImmuCell estimates fees of $100,000 this year in connection with the initial supply of clinical materials to Novatreat (3/12)

Incyte Genomics Inc. (INCY)

Eisai Co. Ltd. (Japan)

Multiyear subscription deal for Incyte's LifeSeq Gold database

ND

Eisai also will subscribe to Incyte's ZooSeq animal model database (4/10)

InfiMed Therapeutics Inc.*

Nikken Chemicals Co. Ltd. (Japan)

Collaboration on the development of Infitropin CR, a product to treat growth

ND

Financial terms of the agreement were not disclosed (4/19)

Innogenetics NV (Belgium; EASDAQ:INNX)

Bayer Corp.

Agreements in the field of in vitro nucleic acid-based viral diagnostics

EUR20.4 (US$18.4)

Bayer gained exclusive worldwide rights for the sale and marketing of Innogenetics' LiPA HIV and LiPA HCV products and their future generations; Bayer will make a payment of EUR10.4M, future milestone payments and research and development funding for the next five years, as well as a EUR10M equity investment in Innogenetics (3/15)

InSite Vision Inc. (AMEX:ISV)

SSP Co. Ltd. (Japan)

Licensing agreement for ophthalmic indications of the fluoroquinolone compounds SS732 and SS734

ND

InSite will develop SS734/DuraSite in the U.S. and Europe, and SSP will develop it for Japan; the companies will split other rights in Asia (4/5)

InterMune Pharmaceuticals Inc. (ITMN)

Boehringer Ingelheim GmbH (Germany)

Strategic alliance for certain development and commercialization rights to interferon gamma-1b, marketed in the U.S. as Actimmune

ND

InterMune will receive a 20% royalty, under certain conditions on the sales of the product (3/26)

Introgen Therapeutics Inc. (INGN)

Aventis Pharma AG (Germany)

Agreement giving Introgen manufacturing and commercial rights to the p53 gene therapy product, INGN 201

$20

Introgen will market the product for head and neck cancer and receive a $20M equity investment from Aventis and a 5% stake in Aventis' spin-off of its Gencell therapy division (4/3)

Lynx Therapeutics Inc. (LYNX)

AstraZeneca plc (UK)

Collaboration to apply Lynx's Megatype technology for genome-wide scans to discover single nucleotide polymorphisms associated with asthma

ND

Lynx will receive up-front and milestone payments (3/20)

Lynx Therapeutics Inc. (LYNX)

AstraZeneca plc (UK)

Collaborative research agreement that aims to identify genes that are differentially expressed between different human tissues

ND

Lynx will analyze AstraZeneca samples using Megasort technology and will receive milestone payments (4/4)

MDS Proteomics Inc. (Canada; unit of MDS Inc.; NYSE: MDZ; TSE:MDS)

Partners Healthcare Inc.

Clinical research alliance to study protein-to-protein pathways

ND

No further details were disclosed (3/27)

Medarex Inc. (MEDX)

Novo Nordisk A/S (Denmark)

Alliance to develop fully human antibody therapeutics

ND

Alliance will combine Medarex's UltiMAb Human Antibody Development System and T-12 Development with Novo Nordisk's fusion protein expertise; Novo Nordisk will develop and commercialize any resulting products and Medarex will receive up-front payments, as well as milestones and royalties (1/9)

Medarex Inc. (MEDX)

Schering-Plough Corp.

Research alliance to develop fully human antibodies against multiple disease targets

ND

Schering-Plough receives options on exclusive commercial rights to drugs that come out of the collaboration; Medarex will receive license fees, milestone payments and royalties (3/29)

Message Pharmaceuticals Inc.*

Aventis Pharmaceuticals Inc.

Collaboration to investigate post-transcriptional regulatory mechanisms associated with a number of genes of interest

ND

Message will apply its Scribe technology to the collaboration (3/19)

Millennium Pharmaceuticals Inc. (MLNM)

Abbott Laboratories Inc.

Agreement to develop therapeutics focused on obesity and diabetes

$250

Under the five-year agreement, Abbott will buy $50M in Millennium stock when the deal closes, and $200M more over the next two years; the companies will share costs equally, including those for candidates already in their pipelines; the companies are splitting commercialization efforts in the U.S., with Abbott responsible for them in the rest of the world; worldwide profits will be shared (3/12)

Morphochem AG (Germany)*

Aventis Pharma AG (Germany)

Research and development collaboration to use Morpho-chem's high-throughput chemistry to develop compounds that interact with an undisclosed diabetes target

ND

Aventis will pay a success fee, milestones and royalties, and will fund the work (3/22)

Morphochem AG (Germany)*

Sosei Ltd. (Japan)

Agreement to optimize a potential cancer drug

ND

The companies will use capabilities in multicomponent reaction chemistry; results from the collaboration will be shared equally (3/28**)

M-phasys GmbH (Germany)*

GlaxoSmithKline plc (UK)

Research agreement to target the in vitro functionality of a single, undisclosed G protein-coupled receptor

ND

M-phasys will use its M-Fold refolding technology for the research (4/17)

NeoGene Technologies (subsidiary of NeoTherapeutics Inc.; NEOT)

Pfizer Inc.

Agreement focused on NeoGene's milieu, G protein-coupled receptors

ND

Deal includes an initial payment for NeoGene and milestone payments on potential products; Pfizer will partner with NeoGene on one orphan GPCR (3/19)

Neurogenetics Inc.*

Eisai Co. Ltd. (Japan)

Exclusive agreement involving Alzheimer's disease targets

ND

Neurogenetics granted Eisai first negotiation rights to collaborate on selected Alzheimer's disease drug discovery programs (4/24)

NPS Pharmaceuticals Inc. (NPSP)

AstraZeneca plc (UK)

Five-year collaboration in which NPS is licensing its technology related to mGluR, and molecules that act at those receptors, to AstraZeneca

ND

AstraZeneca will match NPS's funding levels and offer NPS options either to co-promote products in North America or get royalties (3/28)

Organogenesis Inc. (AMEX:ORG)

Royce Medical Co.

Collaboration for certain uses of Organogenesis' engineered collagen technology

ND

Financial terms were not disclosed (3/21)

Pharmacopeia Inc. (PCOP)

Mitsubishi-Tokyo Pharmaceuticals (Japan)

Collaboration agreement under which Pharmacopeia will use its assay development knowledge, compound sample collection and ultra-high throughput screening technology to identify compounds against a Mitsubishi target

ND

Pharmacopeia will receive fees and milestone payments and be entitled to royalties (3/29)

Pharmagene plc (UK; LSE:PGN)

Bayer Corp.

Drug discovery agreement in the area of oncology

ND

Pharmagene will identify gene expression patterns across a matrix of diseased and nondiseased human tissue samples, constructed to depict nine cancer types of interest to Bayer (3/7)

Pharmagene plc (UK; LSE:PGN)

Taisho Pharmaceutical Ltd. (Japan)

Phase ZERO agreement

ND

Pharmagene will use human hepatocytes to investigate gene expression profiling and to use human tissue to carry out pharmacological profiling on Taisho compounds (3/9)

Procyon BioPharma Inc. (Canada; OTC BB: PCYBF)

International Medical Innovations Inc. (Canada)

Worldwide exclusive licensing agreement giving IMI rights to develop, market and distribute its colorectal cancer screening technology, Colopath

ND

Procyon will receive an up-front payment, as well as milestones and royalties (3/20)

ProMetic Life Sciences Inc. (Canada)*

Merck KGaA (Germany)

Alliance to jointly market their knowledge of the monoclonal antibody purification field

ND

ProMetic will provide its Mimetic Ligand technology and Merck will provide ion-exchange polymeric bioprocessing media products, as well as its sales force and distribution network (4/10)

RiboTargets Ltd.*

Johnson & Johnson

Development agreement for antibiotics focused around two novel targets on the bacterial ribosome

ND

Two-year deal includes up-front payments (3/14**)

Titan Pharmaceuticals Inc. (AMEX:TTP)

Novartis Pharma AG (Switzerland)

Agreement to develop and commercialize Zomaril in Japan

ND

Titan receives license fees and milestone payments, in addition to royalties on product sales (4/25)

Valentis Inc. (VLTS)

GlaxoSmithKline plc (UK)

Nonexclusive license agreement for GeneSwitch technology for gene regulation

ND

The license is expressly for research (4/12)

X-Ceptor Therapeutics Inc.*

Sankyo Co. Ltd. (Japan)

Research and development agreement focused on selective modulators of the liver X receptor

$45

Deal is worth the full $45M if a product makes it to market; it includes more than $20M in up-front funding and research support (4/9)

NOTES

# The information in the chart does not cover agreements between biotech companies or agricultural agreements. The chart does include some agreements that occurred before March 6, but were not listed in the previous chart.

* Private companies are indicated with an asterisk; unless otherwise noted, stock symbols listed are on the NASDAQ market.

** Denotes the date the item ran in BioWorld International.

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange